Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05113251 · MORE INFO

Limitations, agreements, and source contact

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer · Source last updated 2026-08-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
true
limitations And Caveats
description
On 13 March 2024, enrolment to the T-DXd-alone arm was prematurely closed following the recommendation of the Independent Data Monitoring Committee (IDMC). Patients already receiving T-DXd alone could continue treatment until completion of eight cycles, meeting any discontinuation criteria, or switching to the investigator's choice of local SOC-classified as having a non-pCR.
point Of Contact
email
information.center@astrazeneca.com
organization
AstraZeneca Clinical Study Information Center
phone
1-877-240-9479
title
Global Clinical Lead
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
true
limitations And Caveats
description
On 13 March 2024, enrolment to the T-DXd-alone arm was prematurely closed following the recommendation of the Independent Data Monitoring Committee (IDMC). Patients already receiving T-DXd alone could continue treatment until completion of eight cycles, meeting any discontinuation criteria, or switching to the investigator's choice of local SOC-classified as having a non-pCR.
point Of Contact
email
information.center@astrazeneca.com
organization
AstraZeneca Clinical Study Information Center
phone
1-877-240-9479
title
Global Clinical Lead

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice